ABCL Stock Risk & Deep Value Analysis
Abcellera Biologics Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on ABCL
We analyzed Abcellera Biologics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ABCL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
Get notified when ABCL moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈ABCL Performance Overview3yr weekly
Unlock ABCL Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
ABCL Quality Rating
ABCL Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Abcellera Biologics Inc (ABCL)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$1.19B
ABCL Deep Value Analysis
ABCL Research Sources
No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.
For educational context only. Not financial advice.
ABCL Red Flags & Warning Signs
- ⚠
Negative or inconclusive clinical trial results for ABCL635 or other candidates
- ⚠
Higher-than-expected cash burn and need for dilutive financing
Unlock ABCL Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
ABCL Financial Health Metrics
Market Cap
$1.19B
P/E Ratio
-8.00
Profit Margin
-194.89%
Debt-to-Equity
0.15
Beta (Volatility)
0.97
Earnings Per Share
$-0.49
ABCL Competitive Moat Analysis
Moat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is strengthening as AbCellera's AI platform generates more data, improves its predictive power, and yields successful clinical candidates, increasing its lead over competitors. The unique biological insights gained through its discovery process are difficult to replicate.
ABCL Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
ABCL Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Call (May 11, 2026) with disclosure of interim Phase 1 data for ABCL635
- •Potential new antibody discovery partnership announcements
Medium-Term (6-18 months)
- •Phase 2 results for ABCL635 (expected Q3 2026)
- •Advancement of other pipeline candidates into clinic
Long-Term (18+ months)
- •Approval and commercialization of ABCL635, generating significant royalty revenue
- •Establishment as a dominant AI-powered drug discovery and development partner
Catalysts & Growth Drivers
Sign up free to see growth catalysts
ABCL Bull Case: What Could Go Right
- ✓
Acceleration in royalty or milestone revenue from partnered programs.
- ✓
Strong safety and efficacy data from ABCL635 Phase 2 trials.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Abcellera Biologics Inc (ABCL)?
As of April 21, 2026, Abcellera Biologics Inc has a DVR Score of 7.2 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Abcellera Biologics Inc?
Abcellera Biologics Inc's market capitalization is approximately $1.2B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Abcellera Biologics Inc use?
ABCL is the ticker symbol for Abcellera Biologics Inc. The company trades on the NMS.
What is the risk level for ABCL stock?
Our analysis rates Abcellera Biologics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ABCL?
Abcellera Biologics Inc currently has a price-to-earnings (P/E) ratio of -8.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Abcellera Biologics Inc's revenue growing?
Abcellera Biologics Inc has reported revenue growth of 160.6%. The company is showing strong top-line momentum.
Is ABCL stock profitable?
Abcellera Biologics Inc has a profit margin of -194.9%. The company is currently unprofitable.
How often is the ABCL DVR analysis updated?
Our AI-powered analysis of Abcellera Biologics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 21, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.